Denali TherapeuticsDNLI
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 390
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
72% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.17M
33% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 58
31% more capital invested
Capital invested by funds: $2.81B [Q2] → $3.69B (+$875M) [Q3]
7% more funds holding
Funds holding: 201 [Q2] → 215 (+14) [Q3]
3.52% more ownership
Funds ownership: 84.89% [Q2] → 88.41% (+3.52%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JP Morgan Jessica Fye 47% 1-year accuracy 18 / 38 met price target | 9%upside $24 | Overweight Maintained | 7 Jan 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 109 / 339 met price target | 297%upside $87 | Buy Maintained | 7 Jan 2025 |
Baird Joel Beatty 48% 1-year accuracy 20 / 42 met price target | 41%upside $31 | Outperform Initiated | 7 Jan 2025 |
Stifel Paul Mattels 0% 1-year accuracy 0 / 1 met price target | 69%upside $37 | Buy Upgraded | 16 Dec 2024 |
Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target | 105%upside $45 | Buy Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 8 articles about DNLI published over the past 30 days
